Testing Procedures in Cutaneous Systemic Immune-Related Adverse Drug Reactions

  • Jean-Marie Lachapelle
Chapter

Abstract

Cutaneous adverse drug reactions (CADRs) to systemically administered drugs have increased in number during the last few years. This is due to the expanding number of new active molecules used in the treatment of a variety of diseases. CADRs are varied and described in full detail in oriented manuals of dermatology.

Diagnosis of CADR may be straightforward in some cases but less obvious in some others. The link between the occurrence of a CADR and the systemic administration of a drug (considered to be the culprit agent) is sometimes difficult to assess. The problem is even more complex when several drugs are administrated concomitantly. Several criteria can be taken into account to find the relationship between drug administration and the occurrence of CADRs.

Keywords

Patch Test Allergic Contact Dermatitis Pure Drug Intradermal Test Patch Test Reaction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Breathnach SM, Hinter H (1992) Adverse drug reactions and the skin. Blackwell Scientific Publications, OxfordGoogle Scholar
  2. 2.
    Zürcher K, Krebs A (1992) Cutaneous drug reactions. An integral synopsis of today’s systemic drugs, 2nd edn. Karger, BaselGoogle Scholar
  3. 3.
    Pirchler WJ (2007) Drug hypersensitivity. Karger, BaselGoogle Scholar
  4. 4.
    Litt JZ (2011) Litt’s drug eruption reference manual, 14th edn. Informa Healthcare, LondonGoogle Scholar
  5. 5.
    Bégaud B, Evreux JC, Jouglard J, Lagier G (1985) Unexpected or toxic drug reaction assessment (imputation). Actualization of the method used in France. Therapie 40:111–118PubMedGoogle Scholar
  6. 6.
    Moore N, Paux G, Begaud B, Biour M, Loupi E, Boismare F, Royer RJ (1985) Adverse drug reaction monitoring: doing it the French way. Lancet 2:1056–1058PubMedCrossRefGoogle Scholar
  7. 7.
    Friedmann P (2003) Mechanisms in cutaneous drug hypersensitivity. Clin Exp Allergy 33:861–872PubMedCrossRefGoogle Scholar
  8. 8.
    Gonçalo M, Bruynzeel D (2011) Patch testing in adverse drug reactions. In: Johansen JD, Frosch PJ, Lepoittevin J-P (eds) Contact dermatitis, 5th edn. Springer, Berlin, pp 475–491CrossRefGoogle Scholar
  9. 9.
    Weedon D (2007) Skin pathology, 2nd edn. Churchill Livingstone, EdinburghGoogle Scholar
  10. 10.
    Barbaud A, Gonçalo M, Bruynzeel D, Bircher A (2001) Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse Drug hypersensitivity reactions. Contact Dermatitis 45:321–328PubMedCrossRefGoogle Scholar
  11. 11.
    Barbaud A (2007) Place of drug skin tests. In: Pirchler WJ (ed). Karger, Basel, pp 366–379Google Scholar
  12. 12.
    Barbaud A (2007) Drug skin tests and systemic cutaneous adverse drug reactions: an update. Expert Rev Dermatol 2:4, www.Future-drugs.com CrossRefGoogle Scholar
  13. 13.
    Barbaud A (2009) Skin testing in delayed reactions to drugs. Immunol Allergy Clin North Am 29:517–535PubMedCrossRefGoogle Scholar
  14. 14.
    Lammintausta K, Kortekangas-Savolainen O (2005) The usefulness of skin tests to prove drug hypersensitivity. Br J Dermatol 152:968–974PubMedCrossRefGoogle Scholar
  15. 15.
    Friedmann PS, Arden-Jones M (2010) Patch testing in drug allergy. Curr Opin Allergy Clin Immunol 10:291–296PubMedCrossRefGoogle Scholar
  16. 16.
    Halevy S (2009) Acute generalized exanthematous pustulosis. Curr Opin Allergy Clin Immunol 9:322–328PubMedCrossRefGoogle Scholar
  17. 17.
    Endo JO, Davis C, Powell PC (2011) The potential utility of patch testing in identifying the causative agent of morbilliform drug eruptions. Dermatitis 22:114–115PubMedGoogle Scholar
  18. 18.
    Vaillant L, Camenen I, Lorette G (1989) Patch testing with carbamazepine: reinduction of an exfoliative dermatitis. Arch Dermatol 125:299PubMedCrossRefGoogle Scholar
  19. 19.
    Andrade P, Brinca A, Gonçalo M (2011) Patch testing in fixed drug eruptions – a 20-year review. Contact Dermatitis 65:195–201PubMedCrossRefGoogle Scholar
  20. 20.
    Santiago F, Gonçalo M, Brites M et al (2008) Drug hypersensitivity syndrome (DRESS): what patch tests can reveal us. Contact Dermatitis 58:S17Google Scholar
  21. 21.
    Santiago F, Gonçalo M, Vieira R et al (2010) Epicutaneous patch testing in the diagnosis of drug hypersensitivity syndrome (DRESS). Contact Dermatitis 62:47–53PubMedCrossRefGoogle Scholar
  22. 22.
    Veien N, Menné T, Maibach HI (2008) Systemic contact-type dermatitis. In: Zhai H, Wilhelm K-P, Maibach HI (eds) Marzulli and Maibach’s dermatotoxicology, 7th edn. CRC, Boca Raton, pp 139–153Google Scholar
  23. 23.
    Barbaud A (2007) Tests cutanés médicamenteux dans l’exploration des toxideemies. In: Progrès en Dermato-Allergologie. John Libbey Eurotext, Paris, Montrouge, pp 337–351Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • Jean-Marie Lachapelle
    • 1
  1. 1.Department of DermatologyCatholic University of LouvainBrusselsBelgium

Personalised recommendations